2026-2034年被忽视的热带疾病全球市场规模、份额、趋势和成长分析报告

被忽视的热带疾病 (NTD) 市场预计将从 2025 年的 45.4 亿美元增长到 2034 年的 69 亿美元，2026 年至 2034 年的复合年增长率为 4.77%。

随着越来越多的全球卫生倡议致力于在低收入地区防治感染疾病，被忽视的热带疾病的全球市场日益受到关注。各国政府、非政府组织和世界卫生组织都在加大对研究、治疗和预防计画的投入。登革热、利什曼原虫症和南美锥虫病等疾病的负担持续推动对有效治疗方法和诊断方法的需求。新的资金筹措机制和伙伴关係正在促进市场发展。

关键驱动因素包括公众对疾病认知的提高、流行地区医疗保健服务的扩展以及世界卫生组织的支持。公私合营正在加速药物研发和分发，而诊断技术和疫苗研究的进步则进一步加强了疾病控制策略。此外，慈善资金和政策架构也鼓励製药公司参与被忽视疾病防治计画。

随着生物製药、疫苗和标靶治疗的持续创新，未来前景一片光明。加强发展中地区的医疗卫生基础设施将有助于扩大治疗覆盖范围。研究机构、政府和製药公司之间加强合作将推动研发管线的开发。在全球日益关注医疗公平的背景下，被忽视的热带疾病市场预计将保持持续成长，并带来长期的投资机会。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：被忽视的全球热带疾病市场：依疾病类型划分

• 市场分析、洞察与预测
• 地中海热
• 伊波拉病毒感染疾病
• 南美锥虫病
• 兹卡病毒感染疾病
• 基孔古尼亚
• 其他的

第五章：全球被忽视的热带疾病市场：依治疗方法

• 市场分析、洞察与预测
• 药物
• 疫苗

第六章：全球被忽视的热带疾病市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 注射药物

第七章：全球被忽视的热带疾病市场：以最终用户划分

• 市场分析、洞察与预测
• 医院
• 居家照护
• 专科诊所
• 其他的

第八章：全球被忽视的热带疾病市场：按分销管道划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 其他的

第九章：被忽视的全球热带疾病市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十一章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Emergent BioSolutions Inc
  • Moderna
  • Valneva SE
  • Johnson & Johnson Services
  • DAIICHI SANKYO COMPANY
  • LIMITED
  • Insud Pharma Group
  • Humanigen Inc
  • Savant HWP Inc
  • Bayer AG
  • Eisai Co. Ltd
  • Oblita Therapeutics
  • GlaxoSmithKline Plc
  • Themis Bioscience GmbH
  • Novartis AG

The Neglected Tropical Diseases Market size is expected to reach USD 6.90 Billion in 2034 from USD 4.54 Billion (2025) growing at a CAGR of 4.77% during 2026-2034.

The global neglected tropical diseases market has gained attention due to increasing global health initiatives aimed at combating infectious diseases in low-income regions. Governments, non-governmental organizations, and international health agencies are investing in research, treatment, and prevention programs. The burden of diseases such as dengue, leishmaniasis, and Chagas disease continues to drive demand for effective therapeutics and diagnostics. Emerging funding mechanisms and partnerships have strengthened market development.

Key drivers include rising disease awareness, expanded healthcare access in endemic regions, and support from global health organizations. Public-private partnerships have accelerated drug development and distribution. Advances in diagnostic technologies and vaccine research have further enhanced disease management strategies. Additionally, philanthropic funding and policy frameworks are encouraging pharmaceutical companies to participate in neglected disease programs.

Future prospects appear positive as innovation in biologics, vaccines, and targeted therapies continues. Strengthening healthcare infrastructure in developing regions will support wider treatment access. Increased collaboration among research institutions, governments, and pharmaceutical firms will drive pipeline development. As global focus on equitable healthcare intensifies, the neglected tropical diseases market is expected to witness sustained growth and long-term investment opportunities.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disease Type

• Mediterranean Fever
• Ebola Virus Infection
• Chagas Disease
• Zika Virus Infection
• Chikungunya
• Others

By Treatment

• Drugs
• Vaccine

By Route of Administration

• Oral
• Injectable

By End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

COMPANIES PROFILED

• Emergent BioSolutions Inc, Moderna, Valneva SE, Johnson Johnson Services, DAIICHI SANKYO COMPANY, LIMITED, Insud Pharma Group, Humanigen Inc, Savant HWP Inc, Bayer AG, Eisai Co Ltd, Oblita Therapeutics, GlaxoSmithKline plc, Themis Bioscience GmbH, Novartis AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease Type
• 4.2. Mediterranean Fever Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Ebola Virus Infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Chagas Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Zika Virus Infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Chikungunya Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY TREATMENT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment
• 5.2. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Disease Type
  • 9.2.2 By Treatment
  • 9.2.3 By Route Of Administration
  • 9.2.4 By End User
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Disease Type
  • 9.3.2 By Treatment
  • 9.3.3 By Route Of Administration
  • 9.3.4 By End User
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Disease Type
  • 9.4.2 By Treatment
  • 9.4.3 By Route Of Administration
  • 9.4.4 By End User
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Disease Type
  • 9.5.2 By Treatment
  • 9.5.3 By Route Of Administration
  • 9.5.4 By End User
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Disease Type
  • 9.6.2 By Treatment
  • 9.6.3 By Route Of Administration
  • 9.6.4 By End User
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL NEGLECTED TROPICAL DISEASES INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Emergent BioSolutions Inc
  • 11.2.2 Moderna
  • 11.2.3 Valneva SE
  • 11.2.4 Johnson & Johnson Services
  • 11.2.5 DAIICHI SANKYO COMPANY
  • 11.2.6 LIMITED
  • 11.2.7 Insud Pharma Group
  • 11.2.8 Humanigen Inc
  • 11.2.9 Savant HWP Inc
  • 11.2.10 Bayer AG
  • 11.2.11 Eisai Co. Ltd
  • 11.2.12 Oblita Therapeutics
  • 11.2.13 GlaxoSmithKline Plc
  • 11.2.14 Themis Bioscience GmbH
  • 11.2.15 Novartis AG